Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
作者： Stefan W. Metz , Byron E. Martina , Petra van den Doel , Corinne Geertsema , Albert D. Osterhaus
DOI: 10.1016/J.VACCINE.2013.09.045
关键词:
摘要: Chikungunya virus (CHIKV) causes acute illness characterized by fever and long-lasting arthritic symptoms. The need for a safe effective vaccine against CHIKV infections is on the rise due to on-going vector spread increasing severity of clinical complications. Here we report results comparative vaccination-challenge experiment in mice using three different candidates produced insect cells recombinant baculoviruses: (i) secreted (s)E1 (ii) sE2 glycoprotein subunits (2 μg/immunization), (iii) virus-like particles (VLPs) (1 μg E2 equivalent/immunization). These experiments show that vaccination with two subsequent administrations 1 Matrix M adjuvanted VLPs completely protected AG129 from lethal challenge. Vaccination E1 provided partial protection, half surviving but significantly lower neutralizing antibody titres as compared VLP vaccinated mice. This study provides evidence even modest response sufficient protect infections. Neutralization was prominent correlate protection. In addition, provide superior immune protection CHIKV-induced disease individual CHIKV-sE1 -sE2 subunits.
pfizerpro.com.co参考文章(24)
Loreen A. Hodgson, George V. Ludwig, Jonathan F. Smith, Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors1In conducting the research described in this report, the investigators adhered to the Guide for Care and Use of Laboratory Animals, as promulgated by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care. The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.1 Vaccine. ,vol. 17, pp. 1151- 1160 ,(1999) , 10.1016/S0264-410X(98)00335-1
M. Enserink, Chikungunya: No Longer a Third World Disease Science. ,vol. 318, pp. 1860- 1861 ,(2007) , 10.1126/SCIENCE.318.5858.1860
E.A. Gould, P. Gallian, X. de Lamballerie, R.N. Charrel, First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clinical Microbiology and Infection. ,vol. 16, pp. 1702- 1704 ,(2010) , 10.1111/J.1469-0691.2010.03386.X
E G Strauss, D S Stec, A L Schmaljohn, J H Strauss, Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants. Journal of Virology. ,vol. 65, pp. 4654- 4664 ,(1991) , 10.1128/JVI.65.9.4654-4664.1991
Monique M. van Oers, Opportunities and challenges for the baculovirus expression system Journal of Invertebrate Pathology. ,vol. 107, pp. S3- S15 ,(2011) , 10.1016/J.JIP.2011.05.001
Ann M. Powers, Christopher H. Logue, Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus Journal of General Virology. ,vol. 88, pp. 2363- 2377 ,(2007) , 10.1099/VIR.0.82858-0
Sudhanshu Vrati, Carol A. Fernon, Lynn Dalgarno, Ronald C. Weir, Location of a major antigenic site involved in Ross River virus neutralization Virology. ,vol. 162, pp. 346- 353 ,(1988) , 10.1016/0042-6822(88)90474-6
Eryu Wang, Eugenia Volkova, A. Paige Adams, Naomi Forrester, Shu-Yuan Xiao, Ilya Frolov, Scott C. Weaver, CHIMERIC ALPHAVIRUS VACCINE CANDIDATES FOR CHIKUNGUNYA Vaccine. ,vol. 26, pp. 5030- 5039 ,(2008) , 10.1016/J.VACCINE.2008.07.054
Rob Noad, Polly Roy, None, Virus-like particles as immunogens Trends in Microbiology. ,vol. 11, pp. 438- 444 ,(2003) , 10.1016/S0966-842X(03)00208-7
Diego Ruiz-Moreno, Irma Sanchez Vargas, Ken E. Olson, Laura C. Harrington, Modeling Dynamic Introduction of Chikungunya Virus in the United States PLOS Neglected Tropical Diseases. ,vol. 6, ,(2012) , 10.1371/JOURNAL.PNTD.0001918